Raymond James & Associates Nuvalent, Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Nuvalent, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 4,690 shares of NUVL stock, worth $342,370. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,690Holding current value
$342,370% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NUVL
# of Institutions
183Shares Held
54.4MCall Options Held
838KPut Options Held
116K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.46 Billion31.01% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.18MShares$305 Million11.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.41MShares$249 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.78MShares$203 Million4.39% of portfolio
-
Black Rock Inc. New York, NY2.71MShares$198 Million0.0% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.14B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...